晚期或转移性尿路上皮癌的免疫治疗:一项精简版Cochrane综述
该Cochrane综述评估免疫治疗对比化疗用于晚期或转移性尿路上皮癌一线及二线治疗的效果。纳入5项随机对照试验及7项单臂研究,采用GRADE分级评价证据质量。一线免疫治疗对总死亡风险几乎无影响,二线可能降低总死亡风险;免疫治疗可能减少3-5级不良事件,健康相关生活质量未见明显受影响。
要点
- 一线免疫治疗对比化疗对总死亡风险几乎无影响(HR 0.97,95%CI 0.87-1.07;中等质量证据)。
- 二线免疫治疗可能降低总死亡风险(HR 0.72,95%CI 0.63-0.81;低质量证据)。
- 免疫治疗可能减少3-5级不良事件,一线RR 0.47(95%CI 0.29-0.75),二线RR 0.89(95%CI 0.81-0.97)。
核心结论
- 对比化疗,免疫治疗一线用于晚期或转移性尿路上皮癌对总死亡风险几乎无影响,二线可能降低总死亡风险。
- 一线及二线免疫治疗对健康相关生活质量似乎无影响。
- 免疫治疗一线可能减少、二线可能减少3-5级不良事件。
研究设计与样本
- 基于已发表方案对多个数据库进行系统检索,纳入5项随机对照试验并识别7项单臂研究。
- 两名评价作者独立完成文献筛选、研究识别、纳入合格性评估及数据提取。
- 采用随机效应模型进行统计分析,并按GRADE方法逐结局评估证据质量。
主要发现
- 一线免疫治疗对比化疗对总死亡风险几乎无影响(HR 0.97,95%CI 0.87-1.07;中等质量证据)。
- 一线免疫治疗对比化疗对健康相关生活质量几乎无影响(MD 4.10,95%CI 3.83-4.37;中等质量证据)。
- 一线免疫治疗对比化疗可能减少3-5级不良事件(RR 0.47,95%CI 0.29-0.75;中等质量证据)。
- 二线免疫治疗对比化疗可能降低总死亡风险(HR 0.72,95%CI 0.63-0.81;低质量证据)。
- 二线免疫治疗对比化疗对健康相关生活质量几乎无影响(MD 4.82,95%CI -3.11至12.75;低质量证据);可能减少3-5级不良事件(RR 0.89,95%CI 0.81-0.97;低质量证据)。
关键数值与推荐
- 一线免疫治疗对比化疗:总死亡风险HR 0.97(95%CI 0.87-1.07),中等质量证据。
- 一线免疫治疗对比化疗:健康相关生活质量MD 4.10(95%CI 3.83-4.37),中等质量证据。
- 一线免疫治疗对比化疗:3-5级不良事件RR 0.47(95%CI 0.29-0.75),中等质量证据。
- 二线免疫治疗对比化疗:总死亡风险HR 0.72(95%CI 0.63-0.81),低质量证据。
- 二线免疫治疗对比化疗:健康相关生活质量MD 4.82(95%CI -3.11至12.75),低质量证据;3-5级不良事件RR 0.89(95%CI 0.81-0.97),低质量证据。
临床怎么用
- 作者结论认为,一线免疫治疗对比化疗对总死亡风险几乎无影响,二线可能降低总死亡风险。
- 作者结论认为,一线及二线免疫治疗对健康相关生活质量似乎无影响。
- 作者结论认为,免疫治疗一线可能减少、二线可能减少3-5级不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effects of immunotherapy compared to chemotherapy as first- and second-line treatment of advanced or metastatic urothelial carcinoma. METHODS: Based on a published protocol, we performed a systematic search of multiple databases. Two review authors independently performed the literature selection, identified relevant studies, assessed the eligibility of studies for inclusion, and extracted data. We performed statistical analyses using a random-effects model and assessed the quality of the evidence on a per-outcome basis according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included five randomised controlled trials and also identified seven single-arm studies. When used as first-line therapy, immunotherapy probably has little to no effect on the risk of death from any cause compared to chemotherapy (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.87-1.07; moderate-certainty evidence). immunotherapy probably has little to no effect on health-related quality of life (mean difference [MD] 4.10, 95% CI 3.83-4.37; moderate). Immunotherapy probably reduces grade 3-5 adverse events (risk ratio [RR] 0.47, 95% CI 0.29-0.75; moderate). In the second-line setting immunotherapy may reduce the risk of death from any cause (HR 0.72, 95% CI 0.63-0.81; low). Immunotherapy may have little to no effect on health-related quality of life when compared to chemotherapy (MD 4.82, 95% CI -3.11 to 12.75; low). Immunotherapy may reduce grade 3-5 adverse events (RR 0.89, 95% CI 0.81-0.97; low). CONCLUSIONS: Compared to chemotherapy, immunotherapy has little to no effect on the risk of death from any cause in a first-line setting. Nevertheless, it may reduce the risk of death from any cause when used as second-line therapy. The health-related quality of life of participants receiving first- and second-line therapy does not appear to be affected by immunotherapy. Immunotherapy probably reduces or may reduce grade 3-5 adverse events when used as first- and second-line therapy, respectively.
引用
- Maisch P, Hwang EC, Kim K, et al. Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review. BJU Int. 2024. PMID: 38658182. doi:10.1111/bju.16368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。